United Therapeutics Insider Mesa Offloads $187K in Stock

Rhea-AI Filing Summary

United Therapeutics Corporation (UTHR) – Form 4 insider transaction

Director Nilda Mesa reported the sale of 645 common shares on 24-Jun-2025 at a weighted-average price of $289.99 (actual trade range: $289.68-$290.05). Following the sale, Mesa’s direct holdings declined to 4,883 shares. No derivative securities were involved and no 10b5-1 trading plan was indicated.

The filing was signed under power of attorney on 25-Jun-2025. No other transactions, options, or changes in indirect ownership were disclosed.

Positive

• None.

Negative

• Director sells 645 shares, signalling mild insider-sentiment deterioration, though financial impact is immaterial.

Insights

Securities Analyst

TL;DR: Small director-level sale (645 shares) at ~$290; immaterial to float but mildly negative insider-sentiment signal.

The transaction represents roughly US$187k in proceeds and reduces the director’s position to just under 5 k shares. This is a modest disposal relative to United Therapeutics’ 47 m share float and does not alter control dynamics. However, insider selling—particularly absent a disclosed 10b5-1 plan—can be interpreted as slightly bearish on near-term valuation. Volume and timing (single-day execution across multiple trades) suggest routine portfolio diversification rather than strategic divestment. Investors should view the impact as limited but monitor for additional insider activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mesa Nilda

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/24/2025		S		645	D	$289.9926(1)	4,883	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $289.68 to $290.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many United Therapeutics (UTHR) shares did Director Nilda Mesa sell?

Mesa disposed of 645 common shares on 24-Jun-2025.

At what price were the UTHR shares sold according to the Form 4?

The weighted-average sale price was $289.99, with trades ranging from $289.68 to $290.05.

How many UTHR shares does Nilda Mesa own after the transaction?

After the sale, Mesa directly owns 4,883 shares of United Therapeutics.

Was a Rule 10b5-1 trading plan disclosed in this Form 4 filing?

No; the filing does not indicate that the sale was made under a Rule 10b5-1(c) plan.

Does the Form 4 report any derivative securities for Nilda Mesa?

No derivative securities were acquired, disposed of, or held in this filing.